AU2001278927A1 - Cyclic oxyguanidine pyrazinones as protease inhibitors - Google Patents

Cyclic oxyguanidine pyrazinones as protease inhibitors

Info

Publication number
AU2001278927A1
AU2001278927A1 AU2001278927A AU7892701A AU2001278927A1 AU 2001278927 A1 AU2001278927 A1 AU 2001278927A1 AU 2001278927 A AU2001278927 A AU 2001278927A AU 7892701 A AU7892701 A AU 7892701A AU 2001278927 A1 AU2001278927 A1 AU 2001278927A1
Authority
AU
Australia
Prior art keywords
methyl
pyrazin
acetamide
oxo
ethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278927A
Other languages
English (en)
Inventor
Roger Francis Bone
Tianbao Lu
Richard M Soll
John C. Spurlino
Bruce E Tomczuk
Aihua Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3 Dimensional Pharmaceuticals Inc
Original Assignee
3 Dimensional Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3 Dimensional Pharmaceuticals Inc filed Critical 3 Dimensional Pharmaceuticals Inc
Publication of AU2001278927A1 publication Critical patent/AU2001278927A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2001278927A 2000-07-17 2001-07-17 Cyclic oxyguanidine pyrazinones as protease inhibitors Abandoned AU2001278927A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21870900P 2000-07-17 2000-07-17
US60218709 2000-07-17
PCT/US2001/022302 WO2002006248A2 (en) 2000-07-17 2001-07-17 Cyclic oxyguanidine pyrazinones as protease inhibitors

Publications (1)

Publication Number Publication Date
AU2001278927A1 true AU2001278927A1 (en) 2002-01-30

Family

ID=22816169

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278927A Abandoned AU2001278927A1 (en) 2000-07-17 2001-07-17 Cyclic oxyguanidine pyrazinones as protease inhibitors

Country Status (8)

Country Link
US (3) US6476016B2 (ja)
EP (1) EP1303510A2 (ja)
JP (1) JP2004504305A (ja)
KR (1) KR20030015393A (ja)
AU (1) AU2001278927A1 (ja)
CA (1) CA2415932A1 (ja)
MX (1) MXPA03000512A (ja)
WO (1) WO2002006248A2 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1303510A2 (en) * 2000-07-17 2003-04-23 3-Dimensional Pharmaceuticals, Inc. Cyclic oxyguanidine pyrazinones as protease inhibitors
WO2010132554A2 (en) 2009-05-12 2010-11-18 Mallinckrodt Inc. Diaza heterocyclic compounds for phototherapy
US8731655B2 (en) 2009-05-12 2014-05-20 Mallinckrodt Llc Compounds containing acyclic N-N bonds for phototherapy
RU2019121905A (ru) * 2010-12-31 2019-09-03 Астразенека Юкей Лимитед Ингибиторы аргиназы и способы их применения
US9788539B2 (en) 2011-05-17 2017-10-17 Velico Medical, Inc. Platelet protection solution having beta-galactosidase and sialidase inhibitors
JP2014515352A (ja) 2011-05-17 2014-06-30 ベリコ メディカル インコーポレイティッド シアリダーゼ阻害剤を用いた血小板の保存の改善法
EP2903430A1 (en) 2012-10-05 2015-08-12 Velico Medical, Inc. Platelet additive solution having a beta-galactosidase inhibitor
WO2014120886A1 (en) 2013-01-30 2014-08-07 Velico Medical, Inc. Platelet additive solution having a self-assembling hydrogel-forming peptide
EP3522877B1 (en) * 2016-10-05 2023-12-06 University of Pittsburgh - Of the Commonwealth System of Higher Education Small molecule ampk activators
FR3130591A1 (fr) * 2021-12-20 2023-06-23 L'oreal N-oxalylglycine, ses precurseurs et derives pour epaissir les cheveux

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
ZA897515B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
EP0604022A1 (en) 1992-12-22 1994-06-29 Advanced Cardiovascular Systems, Inc. Multilayered biodegradable stent and method for its manufacture
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
GB9318637D0 (en) 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors
US6087479A (en) 1993-09-17 2000-07-11 Nitromed, Inc. Localized use of nitric oxide-adducts to prevent internal tissue damage
US5466811A (en) 1994-07-18 1995-11-14 Merck & Co., Inc. Dioxolenylmethyl carbamates pro moieties for amine drugs
US5643580A (en) 1994-10-17 1997-07-01 Surface Genesis, Inc. Biocompatible coating, medical device using the same and methods
ES2235174T3 (es) 1994-10-17 2005-07-01 Kabushikikaisha Igaki Iryo Sekkei Stent liberador de medicamento.
DE69526677T2 (de) 1994-12-13 2002-12-05 Corvas Int Inc Aromatische heterocyclische derivate als enzyminhibitoren
US6011158A (en) 1994-12-13 2000-01-04 Corvas International, Inc. Aromatic heterocyclic derivatives as enzyme inhibitors
US5637113A (en) 1994-12-13 1997-06-10 Advanced Cardiovascular Systems, Inc. Polymer film for wrapping a stent structure
DE19514104C2 (de) 1995-04-13 1997-05-28 Behringwerke Ag Beschichtung für in den Blutstrom oder in das Gewebe des menschlichen Körpers einbringbares Biomaterial
CA2224437A1 (en) 1995-06-27 1997-01-16 Merck & Co., Inc. Pyridinone-thrombin inhibitors
CA2233344A1 (en) 1995-09-29 1997-04-03 3-Dimensional Pharmaceuticals, Inc. Guanidino protease inhibitors
CA2245811A1 (en) 1996-02-22 1997-08-28 Merck & Co., Inc. Pyridinone thrombin inhibitors
ATE341317T1 (de) 1996-03-29 2006-10-15 Ortho Mcneil Pharm Inc Amidinohydrazone als protease-inhibitoren
JP3140790B2 (ja) * 1996-04-23 2001-03-05 メルク エンド カンパニー インコーポレーテッド ピラジノン系トロンビン阻害薬
CN1169791C (zh) 1996-09-06 2004-10-06 日本化药株式会社 新颖的乙酰胺衍生物和蛋白酶抑制剂
AU4172397A (en) 1996-09-06 1998-03-26 Biochem Pharma Inc. Lactam inhibitors of thrombin
EP0932615A1 (en) 1996-10-11 1999-08-04 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
TW499412B (en) 1996-11-26 2002-08-21 Dimensional Pharm Inc Aminoguanidines and alkoxyguanidines as protease inhibitors
JP2001508796A (ja) 1997-01-22 2001-07-03 メルク エンド カンパニー インコーポレーテッド トロンビン阻害薬
EP1017393A4 (en) 1997-09-05 2002-01-23 Merck & Co Inc PYRAZINONE-BASED THROMBIN INHIBITORS
AU751412B2 (en) 1997-11-26 2002-08-15 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
WO1999059591A1 (en) 1998-05-19 1999-11-25 Merck & Co., Inc. Pyrazinone thrombin inhibitors
AU742178B2 (en) 1998-05-26 2001-12-20 Merck & Co., Inc. Imidazopyridine thrombin inhibitors
CA2334679C (en) 1998-06-11 2012-10-23 3-Dimensional Pharmaceuticals, Inc. Pyrazinone protease inhibitors
GB2343180A (en) * 1998-10-30 2000-05-03 Merck & Co Inc Process for making pyrazinone compounds used as thrombin inhibitors
EP1189901A1 (en) 1999-05-27 2002-03-27 3-Dimensional Pharmaceuticals, Inc. Oxazaheterocycles as protease inhibitors
EP1303510A2 (en) * 2000-07-17 2003-04-23 3-Dimensional Pharmaceuticals, Inc. Cyclic oxyguanidine pyrazinones as protease inhibitors

Also Published As

Publication number Publication date
KR20030015393A (ko) 2003-02-20
US20020052357A1 (en) 2002-05-02
CA2415932A1 (en) 2002-01-24
US6476016B2 (en) 2002-11-05
US20060058291A1 (en) 2006-03-16
US20030073702A1 (en) 2003-04-17
WO2002006248A3 (en) 2002-04-04
US7030110B2 (en) 2006-04-18
EP1303510A2 (en) 2003-04-23
JP2004504305A (ja) 2004-02-12
MXPA03000512A (es) 2003-10-06
WO2002006248A2 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
US6514978B2 (en) Thromboresistant materials incorporating pyrazinone protease inhibitors
US20060058291A1 (en) Cyclic oxyguanidine pyrazinones as protease inhibitors
EP1324981B1 (en) Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl- substituted phenyl acetamides as protease inhibitors
US6326492B1 (en) Heterocyclic protease inhibitors
US6420397B1 (en) Heteroaryl protease inhibitors and diagnostic imaging agents
US20040254166A1 (en) Substituted phenyl acetamides and their use as protease inhibitors
WO1999055355A1 (en) Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors
MXPA00011612A (en) Pyrazinone protease inhibitors
KR20060103963A (ko) 피라진온 프로테아제 억제제